Vascepa
(Icosapent Ethyl)ApprovedSmall molecule
Vascepa is one of 186 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.
5
Indications
13
Total Trials
4
Active Trials
185
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
63
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
254 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 3
Adrucil
EElorac, Inc.
Phase 3
Vascepa
AAmarin Pharma Inc.
Approved
5-Fu
TToray Industries, Inc
Phase 3
Huaier Granule
QQidong Gaitianli Medicines Co., Ltd
Phase 3
Cytokine-Induced Killer Cells
TThe First People's Hospital of Changzhou
Phase 3
IBI363
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
TQB2102
CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
Leucovorin and 5-FU
AAkeso
Phase 3
HR070803
JJiangsu HengRui Medicine Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cardiovascular2 trials
Aortic Valve Stenosis1 trial
IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion
Active, not recruiting·—·Phase 2·NCT06466278·110 enrolled
COVID-191 trial
Endothelial Function1 trial
Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects
Terminated·—·Phase 3·NCT02422446·2 enrolled
7 more indications
Colorectal Cancer1 trial
Prevention1 trial
Coronary Artery Disease1 trial
A Randomized Controlled Trial Evaluating the Effect of Icosapent Ethyl on High-Risk Coronary Plaques Using 18F-Sodium Fluoride PET/CT
Not yet recruiting·CChina National Center for Cardiovascular Diseases·Approved·NCT07762755·100 enrolled
Regulatory
FDA Approval Timeline[4]
Jul 26, 2012
VASCEPA
NDA NDA202057
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Icosapent Ethyl. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- AAmarin Pharma Inc.
Patent Landscape[5]
Patent Cliff
May 31, 2027
Earliest patent expiration — generic entry possible after this date
Patent #Expires
9700537May 31, 2027
9198892Sep 25, 2027
8399446Feb 9, 2030
8415335Feb 9, 2030
8431560Feb 9, 2030
58 more patents
8546372Feb 9, 2030
8680144Feb 9, 2030
8426399Feb 9, 2030
8518929Feb 9, 2030
8524698Feb 9, 2030
12171738Feb 9, 2030
8617594Apr 29, 2030
8501225Apr 29, 2030
8445013Apr 29, 2030
8445003Apr 29, 2030
8623406Apr 29, 2030
8617593Apr 29, 2030
8454994Apr 29, 2030
8618166Apr 29, 2030
8642077Apr 29, 2030
8703185Apr 29, 2030
8691871Apr 29, 2030
8709475Apr 29, 2030
10010517Apr 29, 2030
10265287Apr 29, 2030
8551521Apr 29, 2030
8563608Apr 29, 2030
11154526Apr 29, 2030
11717504Apr 29, 2030
10792267Apr 29, 2030
10842766Apr 29, 2030
10881632Apr 29, 2030
11103477Apr 29, 2030
11213504Apr 29, 2030
8298554Apr 29, 2030
8669245Jun 15, 2030
8410086Jun 15, 2030
8455472Jun 15, 2030
10842768Jun 15, 2030
8710041Jun 15, 2030
10894028Jun 28, 2033
11369582Jun 28, 2033
11298333Jun 28, 2033
11116742Jun 28, 2033
10568861Jun 28, 2033
10668042Jun 28, 2033
10576054Jun 28, 2033
11000499Jun 28, 2033
9603826Jun 28, 2033
9610272Jun 28, 2033
9623001Jun 28, 2033
9693984Jun 28, 2033
9693985Jun 28, 2033
9693986Jun 28, 2033
10792270Jun 28, 2033
9918954Jun 28, 2033
10278935Jun 28, 2033
10278937Jun 28, 2033
10786478Jun 28, 2033
10278936Jun 28, 2033
10383840Jun 28, 2033
10555925Jun 28, 2033
10555924Jun 28, 2033